Clinical Trial Update: The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating average 24-hour sodium excretion during dapagliflozin treatment in adults with type 2 diabetes and varying renal function, terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Function Impairment
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2, Kidney Function Tests | Phase 4 | Status: TERMINATED | Results posted: 2021-05-28